David J Rawlings
Overview
Explore the profile of David J Rawlings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
7556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watson T, Rosen A, Drow T, Medjo J, MacQuivey M, Ge Y, et al.
Diabetes
. 2025 Mar;
PMID: 40048557
Genome-wide association studies have identified SH2B3 as an important non-MHC gene for islet autoimmunity and type 1 diabetes (T1D). In this study, we found a single SH2B3 haplotype significantly associated...
2.
Pugliano C, Berger M, Ray R, Sapkos K, Wu B, Laird A, et al.
Mol Ther Methods Clin Dev
. 2025 Feb;
32(3):101297.
PMID: 40012884
Targeted gene editing to restore CD40L expression via homology-directed repair (HDR) in CD34 hematopoietic stem and progenitor cells (HSPCs) represents a potential long-term therapy for X-linked hyper IgM syndrome. However,...
3.
Thouvenel C, Tipton C, Yamazaki Y, Zhang T, Rylaarsdam S, Hom J, et al.
J Clin Immunol
. 2025 Jan;
45(1):66.
PMID: 39812873
Reduced function or hypomorphic variants in recombination-activating genes (RAG) 1 or 2 result in a broad clinical phenotype including common variable immunodeficiency (CVID) and even adult-onset disease. Milder RAG variants...
4.
Honaker Y, Gruber D, Jacobs C, Cheng R, Patel S, Galvan C, et al.
Mol Ther
. 2024 Dec;
PMID: 39673129
Pathogenic long-lived plasma cells (LLPCs) secrete autoreactive antibodies, exacerbating autoimmune diseases and complicating solid organ transplantation. Targeted elimination of the autoreactive B cell pool represents a promising therapeutic strategy, yet...
5.
Tewari R, Yang S, McClain E, Hu A, Mortensen E, DeSchmidt A, et al.
J Autoimmun
. 2024 Oct;
149:103327.
PMID: 39476446
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease, characterized by progressive destruction of small intrahepatic bile ducts and portal inflammation. Treatment options are limited, with reliance on liver...
6.
Cheng R, Helmers A, Kreuser S, Dahl N, Honaker Y, Lopez C, et al.
Cell Rep Methods
. 2024 Oct;
4(10):100878.
PMID: 39406231
A key step in developing engineered B cells for therapeutic purposes is evaluation in immunocompetent, large-animal models. Therefore, we developed methods to purify, expand, and differentiate non-human primate (NHP; rhesus...
7.
Watson T, Rosen A, Drow T, Medjo J, MacQuivey M, Ge Y, et al.
bioRxiv
. 2024 Aug;
PMID: 39211124
Article Highlights: The rs3184504 polymorphism, encoding a hypomorphic variant of the negative regulator SH2B3, strongly associates with T1D.SH2B3 deficiency results in hypersensitivity to cytokines, including IL-2, in murine CD4+ and...
8.
Pitner R, Chao J, Dahl N, Fan M, Cai X, Avery N, et al.
Mol Ther
. 2024 Aug;
32(10):3453-3469.
PMID: 39192583
Antibody inhibitors pose an ongoing challenge to the treatment of subjects with inherited protein deficiency disorders, limiting the efficacy of both protein replacement therapy and corrective gene therapy. Beyond their...
9.
Hill T, Narvekar P, Asher G, Edelstein J, Camp N, Grimm A, et al.
Mol Ther
. 2024 Jul;
32(8):2676-2691.
PMID: 38959896
Bispecific antibodies are an important tool for the management and treatment of acute leukemias. As a next step toward clinical translation of engineered plasma cells, we describe approaches for secretion...
10.
Singh A, Al Qureshah F, Drow T, Hou B, Rawlings D
J Immunol
. 2024 Jun;
213(2):135-147.
PMID: 38829130
FOXP3+ regulatory T cells (Treg) are required for maintaining immune tolerance and preventing systemic autoimmunity. PI3Kδ is required for normal Treg development and function. However, the impacts of dysregulated PI3Kδ...